French Institute studies the Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients
Photo by National Cancer Institute
Institut de cancérologie Strasbourg Europe is recruiting patients for the clinical trial of Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients (PROTECT-03).
This study includes the evaluation before and after (neo)adjuvant therapy of:
- one group of patients receiving anthracyclines and taxanes;
- second group of patients receiving anthracyclines, taxanes and trastuzumab.
Change in vastus lateralis cross-sectional area is primary outcome measure.
Among the exclusion criteria are:
- History of cancer
- Previous chemotherapy
- Patients with known chronic pathology
- Pacemaker implantation
- Contraindication to physical condition evaluation
- Contraindication to local anesthesia required for microbiopsy
- Patients < 18 years old or patients ≥ 18 years old under guardianship, or supervision
- Psychiatric, musculoskeletal or neurologic disorders
- Women that are pregnant or breast-feeding
The study will take place at the Institut de Cancerologie Strasbourg Europe, Strasbourg, France, 67033.
The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04638712
